199 related articles for article (PubMed ID: 8038108)
21. Specific effects of n-3 fatty acids and 8-bromo-cGMP on the cyclic nucleotide phosphodiesterase activity in neonatal rat cardiac myocytes.
Picq M; Dubois M; Grynberg A; Lagarde M; Prigent AF
J Mol Cell Cardiol; 1996 Oct; 28(10):2151-61. PubMed ID: 8930810
[TBL] [Abstract][Full Text] [Related]
22. Ca(2+)/calmodulin-dependent cyclic nucleotide phosphodiesterase in cGMP metabolism in rabbit parotid acinar cells.
Sairenji N; Satoh K; Sugiya H
Biomed Res; 2006 Feb; 27(1):37-44. PubMed ID: 16543664
[TBL] [Abstract][Full Text] [Related]
23. Biochemical and pharmacological characterization of cyclic nucleotide phosphodiesterase in airway epithelium.
Rousseau E; Gagnon J; Lugnier C
Mol Cell Biochem; 1994 Nov; 140(2):171-5. PubMed ID: 7898488
[TBL] [Abstract][Full Text] [Related]
24. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension.
Murray F; MacLean MR; Pyne NJ
Br J Pharmacol; 2002 Dec; 137(8):1187-94. PubMed ID: 12466227
[TBL] [Abstract][Full Text] [Related]
25. Implications of PDE4 structure on inhibitor selectivity across PDE families.
Ke H
Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
[TBL] [Abstract][Full Text] [Related]
26. The identification and characterization of two cyclic nucleotide phosphodiesterases from bovine adrenal medulla.
Sabatine JM; Coffee CJ
Arch Biochem Biophys; 1986 Aug; 249(1):95-105. PubMed ID: 3017224
[TBL] [Abstract][Full Text] [Related]
27. [Kinetic properties and regulation of cyclic nucleotide phosphodiesterases in lymphoid cells].
Azhaeva EV; Severin ES
Bioorg Khim; 1987 Sep; 13(9):1157-63. PubMed ID: 2827690
[TBL] [Abstract][Full Text] [Related]
28. The calcium/calmodulin-dependent phosphodiesterase PDE1C down-regulates glucose-induced insulin secretion.
Han P; Werber J; Surana M; Fleischer N; Michaeli T
J Biol Chem; 1999 Aug; 274(32):22337-44. PubMed ID: 10428803
[TBL] [Abstract][Full Text] [Related]
29. Expression and characterization of deletion recombinants of two cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE-3).
He R; Komas N; Ekholm D; Murata T; Taira M; Hockman S; Degerman E; Manganiello VC
Cell Biochem Biophys; 1998; 29(1-2):89-111. PubMed ID: 9631240
[TBL] [Abstract][Full Text] [Related]
30. A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases.
Zhang KY; Card GL; Suzuki Y; Artis DR; Fong D; Gillette S; Hsieh D; Neiman J; West BL; Zhang C; Milburn MV; Kim SH; Schlessinger J; Bollag G
Mol Cell; 2004 Jul; 15(2):279-86. PubMed ID: 15260978
[TBL] [Abstract][Full Text] [Related]
31. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta.
Lugnier C; Schoeffter P; Le Bec A; Strouthou E; Stoclet JC
Biochem Pharmacol; 1986 May; 35(10):1743-51. PubMed ID: 2423089
[TBL] [Abstract][Full Text] [Related]
32. The role of protein phosphorylation in the regulation of cyclic nucleotide phosphodiesterases.
Beltman J; Sonnenburg WK; Beavo JA
Mol Cell Biochem; 1993 Nov; 127-128():239-53. PubMed ID: 7935355
[TBL] [Abstract][Full Text] [Related]
33. A comparative kinetic study of bovine calmodulin-dependent cyclic nucleotide phosphodiesterase isozymes utilizing cAMP, cGMP and their 2'-O-anthraniloyl-,2'-O-(N-methylanthraniloyl)-derivatives as substrates.
Grewal J; Karuppiah N; Mutus B
Biochem Int; 1989 Dec; 19(6):1287-95. PubMed ID: 2561449
[TBL] [Abstract][Full Text] [Related]
34. Effects of fatty acids on activity of cGMP-stimulated cyclic nucleotide phosphodiesterase from calf liver.
Yamamoto T; Yamamoto S; Manganiello VC; Vaughan M
Arch Biochem Biophys; 1984 Feb; 229(1):81-9. PubMed ID: 6322693
[TBL] [Abstract][Full Text] [Related]
35. Role of phosphodiesterase and protein kinase G on nitric oxide-induced inhibition of prolactin release from the rat anterior pituitary.
Velardez MO; De Laurentiis A; del Carmen Díaz M; Lasaga M; Pisera D; Seilicovich A; Duvilanski BH
Eur J Endocrinol; 2000 Aug; 143(2):279-84. PubMed ID: 10913949
[TBL] [Abstract][Full Text] [Related]
36. Photoaffinity labelling of cyclic GMP-inhibited phosphodiesterase (PDE III) in human and rat platelets and rat tissues: effects of phosphodiesterase inhibitors.
Tang KM; Jang EK; Haslam RJ
Eur J Pharmacol; 1994 Jun; 268(1):105-14. PubMed ID: 7925608
[TBL] [Abstract][Full Text] [Related]
37. Isozymes of cyclic-3',5'-nucleotide phosphodiesterases in renal epithelial LLC-PK1 cells.
Rassier ME; McIntyre SJ; Yamaki M; Takeda S; Lin JT; Dousa TP
Kidney Int; 1992 Jan; 41(1):88-99. PubMed ID: 1343559
[TBL] [Abstract][Full Text] [Related]
38. Identification of substrate specificity determinants in human cAMP-specific phosphodiesterase 4A by single-point mutagenesis.
Richter W; Unciuleac L; Hermsdorf T; Kronbach T; Dettmer D
Cell Signal; 2001 Mar; 13(3):159-67. PubMed ID: 11282454
[TBL] [Abstract][Full Text] [Related]
39. Cyclic nucleotide phosphodiesterase-mediated integration of cGMP and cAMP signaling in cells of the cardiovascular system.
Maurice DH
Front Biosci; 2005 May; 10():1221-8. PubMed ID: 15769620
[TBL] [Abstract][Full Text] [Related]
40. [Modern representations of multiple forms of cyclic nucleotide phosphodiesterases in mammalian tissues].
Medvedeva MV
Biokhimiia; 1995 Mar; 60(3):364-86. PubMed ID: 7734612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
